Company Overview and News

Australia Unemployment at 4 Year Low: ETFs in Focus

2017-06-16 zacks
Australia’s unemployment rate has fallen to a four-year low, as almost 42,000 net job additions were made in the month of May. The unemployment rate dropped to 5.5% from 5.7% in April and came below the market estimates of 5.7%. The data released by the Australian Bureau of Statistics (ABS) also stated that the seasonally adjusted workforce participation rate rose to 64.9% in May from 64.8% in April.

Alcoa restores half its Australian aluminium output in wake of blackout

2017-06-09 reuters
MELBOURNE, June 9 Global aluminium maker Alcoa has restarted half the capacity at its aluminium smelter in Australia's Victoria that was crippled by a state-wide blackout six months ago.

UPDATE 1-Alcoa restores half its Australian aluminium output in wake of blackout

2017-06-09 reuters
MELBOURNE Global aluminum maker Alcoa has restarted half the capacity at its aluminum smelter in Australia's Victoria that was crippled by a state-wide blackout six months ago.

2016 AGM speeches


2016 AGM Voting results


Appendix 4G


`Berserk' Aluminum Boom Signals Ore Bonanza for China's Quarry - Bloomberg

2016-04-01 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

‘Berserk’ aluminum boom signals ore bonanza for China’s quarry

2016-03-31 theedgemarkets
MELBOURNE/SHANGHAI (March 31): Key aluminum ingredient bauxite is shaping up as China’s newest obsession in its mission to secure raw materials and once again minerals-rich Australia is a major target.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...